This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dhaher, Y. Articles by Hughes, G. Search for Related Content PubMed PubMed Citation Articles by Dhaher, Y. Articles by Hughes, G. Social Bookmarking                         What's this?

The effect of OM-89 (SUBREUM®) on the murine model of systemic lupus erythematosus MRL-lpr/lpr

Lupus Arthritis Research Unit, St. Thomas' Hospital, London, UK

MA Khamashta

Lupus Arthritis Research Unit, St. Thomas' Hospital, London, UK

B. Hartley

Histology Department, Guy's Hospital, London UK

N. Taub

Department of Public Health Medicine, St. Thomas' Hospital, London, UK

JC Farine

Laboratoires OM S.A., Meyrin/Geneva, CH

Grv Hughes

Lupus Arthritis Research Unit, St. Thomas' Hospital, London, UK

OM-89 (Subreum®), an E. coli extract, is used clinically in the treatment of rheumatoid arthritis.

In this study, the authors examined the effect of OM-89 on some aspects of SLE in the murine model MRL-lpr/lpr. Animals were given OM-89 orally at a dose of 400 mg/kg weight (40 mg active substance) 5 d a week from six weeks old.

It was found that mice receiving the drug reached the point of 55% (6/11) survival at the age of 33 weeks compared with 27 weeks for the control group (54%; 7/13). There was a significant increase in the delay before developing alopecia in the treated group (P < 0.01). The increase in proteinuria in the control group was significantly higher than in the treated group (P < 0.03). In a second set of experiments sacrificing the animals at week 22, a significant decrease in anti-dsDNA auto-antibodies was also found in the treated group (P < 0.05), histopathologically a less severe tubular destruction in the kidney was observed in the treated group. It can be concluded that the oral treatment of OM-89 can significantly reduce the severity of SLE in this strain of mice. It can be postulated that the administration of the bacterial extract could modulate the immune response, modifying the Th1 and Th2 balance and inducing oral tolerance.

Key Words: OM-89 • Subreum • systemic lupus erythematosus • MRL-mice

Lupus, Vol. 6, No. 5, 436-440 (1997)
DOI: 10.1177/096120339700600504


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M.-A. Alyanakian, F. Grela, A. Aumeunier, C. Chiavaroli, C. Gouarin, E. Bardel, G. Normier, L. Chatenoud, N. Thieblemont, and J.-F. Bach Transforming Growth Factor-{beta} and Natural Killer T-Cells Are Involved in the Protective Effect of a Bacterial Extract on Type 1 Diabetes Diabetes, January 1, 2006; 55(1): 179 - 185. [Abstract] [Full Text] [PDF]

				M Chang, S E Walker, and R W Hoffman Immunization with a bacterial ATP-binding cassette transporter fragment suppresses autoimmunity and prolongs survival in MRL/lpr lupus-prone mice Lupus, November 1, 2000; 9(9): 655 - 663. [Abstract] [PDF]